Who are Stryker’s competitors?
Stryker names 15 companies as competitors in its latest annual report, on 4 fronts. 10 companies name Stryker back.
Skip to the field, head to head ↓Stryker company profile
Stryker faces a different set of rivals on each front
Stryker's annual report names 15 competitors, but not as one crowd. It sorts them into four fronts: endoscopy, medical, instruments, and vascular and neuro cranial. In the first it says, "We are one of seven leading global competitors in Endoscopy". In the other three it is one of five. Only three names show up twice: ConMed Linvatec, Medtronic and Johnson & Johnson MedTech. The medical front shares no names with the rest.
Rivals see the same thing from their side. Enovis points to Stryker, Zimmer Biomet and DePuy Synthes in reconstructive. Integra puts Stryker beside Medtronic, Steris and B. Braun in its CSS business. Conmed lists it among joint and sports medicine names such as Smith & Nephew and Arthrex. Each rival meets Stryker in one corner, not across the whole company.
So Stryker's position isn't one contest. It is several, each with its own opponents and its own pace. Stryker brought in $25.1 billion with 11% growth and a 13% net margin. Medtronic, the largest name that appears twice, brought in $36.4 billion with 8% growth and the same margin. Asking who Stryker's competitor is gets a weak answer. Asking which front you mean gets a useful one.
Where Stryker says it competes
“We are one of seven leading global competitors in Endoscopy; the other six being”
“We are one of five leading global competitors in Medical; the other four being Baxter International Inc., Zoll Medical Corporation, Medline Industries and Ferno-Washington, Inc.”
“We are one of five leading global competitors in Instruments; the other four being Zimmer Biomet Holdings, Inc. (Zimmer), Medtronic plc (Medtronic), Johnson & Johnson MedTech (a subsidiary of Johnson & Johnson) and ConMed Linvatec, Inc. (a subsidiary of CONMED Corporation).”
“We are one of five leading global competitors in Vascular and Neuro Cranial; the other four being Medtronic, Johnson & Johnson MedTech, Terumo Corporation and Penumbra, Inc.”
Who names Stryker as a competitor
“On a product basis, competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron and Wassenburg.”
10-K for 2026“Our business is in a very competitive and evolving field, that faces competition from large established orthopedic companies such as (but not limited to) Medtronic, Stryker, Globus Medical, and DePuy-Synthes that possess considerably more resources than Bone Biologics.”
10-K for 2025“We compete with Smith & Nephew, plc; Arthrex, Inc.; Stryker Corporation; Johnson & Johnson: DePuy Mitek, Inc.; Zimmer Biomet, Inc.; Globus Medical, Inc.; and Treace Medical Concepts, Inc.”
10-K for 2025“Key competitors for our Reconstructive segment include Stryker, Zimmer Biomet, and DePuy Synthes, the medical device business within Johnson & Johnson.”
10-K for 2025“We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, and Smith + Nephew.”
10-K for 2025“Our competitors for CSS include divisions within Medtronic, Inc., Stryker Corporation, Steris PLC, and B. Braun Medical, Inc.”
10-K for 2025“Our primary competitors in our spine market are Medtronic, Stryker Corporation, and Johnson & Johnson.”
10-K for 2025“Our most notable competitors are Boston Scientific, Medtronic, Stryker (now including Inari Medical), Terumo and several private companies.”
10-K for 2025“Sports Medicine global market sharea,b In Sports Medicine, Smith+Nephew holds a leading position behind Arthrex, and also competes against Stryker and DePuy Synthes.”
20-F for 2025“In the global markets for our knees, hips, and S.E.T. products, our major competitors include Johnson & Johnson MedTech (formerly the DePuy Synthes Companies of Johnson & Johnson), Stryker Corporation and Smith & Nephew plc.”
10-K for 2025The field, from the filings
| Company | Fiscal year | Revenue | Growth | Net margin | Employees |
|---|---|---|---|---|---|
| Stryker | 2025 | $25.1B | +11% | 13% | 56,000 |
| Medtronic | FY to Apr 2026 | $36.4B | +8% | 13% | – |
| Baxter International | 2025 | $11.2B | +6% | −9% | – |
| Zimmer Biomet Holdings | 2025 | $8.2B | +7% | 9% | – |
| Smith & Nephew | 2025 | $6.2B | +6% | 10% | – |
| Steris | FY to Mar 2026 | $5.9B | +9% | 13% | 18,000 |
| Globus Medical | 2025 | $2.9B | +17% | 18% | 6,000 |
| Enovis | 2025 | $2.2B | +7% | −53% | 7,802 |
| Integra Lifesciences Holdings | 2025 | $1.6B | +2% | −32% | 4,427 |
| Merit Medical Systems | 2025 | $1.5B | +12% | 8% | 7,500 |
| Penumbra | 2025 | $1.4B | +17% | 13% | 4,700 |
Each company’s latest fiscal year as reported to the SEC, in US dollars; fiscal years end in different months. Rivals that report outside the US or in other currencies are not shown.
How concentrated Stryker’s customers are
“Revenue related to customer lease agreements sold under these arrangements represented less than 4 % of our total revenue for 2025 , 2024 and 2023 .”
What the rivals have done lately
“On April 20, 2026, the Company acquired all the remaining outstanding shares of CathWorks Ltd. (CathWorks), a privately held medical device company, for $525 million of consideration transferred, including $115 million of contingent cons…” filing
“On June 12, 2026, the Company closed on the acquisition of all outstanding shares of Scientia Vascular (Scientia) (a privately held company).” filing
“Under the terms of the acquisition, we paid the acquisition price of $122 million and received specified intellectual property, including patent rights, in the first quarter of 2022 and received additional intellectual property, includin…” filing
“On 21 January 2026, we completed the acquisition of Integrity Orthopaedics, Inc, a US-based early stage commercial developer of Tendon Seam™, an innovative rotator cuff repair (RCR) system designed to significantly reduce re-tear rates a…” filing
Decisions that shaped the field
| Medtronic Bought Its Way Into Everything. The Market Just Asked It to Stop. | 2025 | Never undone |
Asked about Stryker’s competitors
Who are Stryker's competitors?
In its annual report for fiscal 2025, Stryker names 15 competitors across 4 fronts: leading global endoscopy competitors, leading global medical competitors, leading global instruments competitors and vascular and neuro cranial competitors. 10-K for fiscal 2025
Which companies name Stryker as a competitor?
10 companies in our coverage name it in their own annual reports: Steris, Bone Biologics, Conmed, Enovis, Globus Medical, Integra Lifesciences Holdings, Merit Medical Systems, Penumbra, Smith & Nephew and Zimmer Biomet Holdings.
How does Stryker compare with its rivals?
Stryker reported $25.1B in revenue in its latest fiscal year, +11% on a year, with a 13% net margin. Medtronic: $36.4B, 13% net margin; Baxter International: $11.2B, −9% net margin.
What are the alternatives to Stryker?
The companies Stryker itself names as competitors are listed above, front by front, each in its own report’s words. Which matters for a given buyer depends on the job, not the list.
How much of your revenue comes from somebody who is also trying to replace you?
Sources: Stryker’s annual report for fiscal 2025; the annual reports of the companies that name it; each company’s financial data as reported to the SEC; Stratrix Decision Records. Analysis and data, not advice.
Keep going
For information and strategic analysis only, not investment advice. Stratrix does not recommend buying, selling or holding any security.
Tools to try
- Ansoff move finderFramework: Ansoff Matrix
- Business model canvas builderFramework: Business Model Canvas
- Change readiness checkFramework: Kotter's 8-Step Change Model
- Five Forces scorerFramework: Porter's Five Forces
- SMART goal builderFramework: SMART Goals
- SWOT builderFramework: SWOT Analysis
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestStratrix Team
Every Casebook, three Strategy Packs a seat each year and Ask Stratrix, for teams that face these decisions all year.
$1,999 a year · $499 a seatWhat is included →New analyses, by email
The defining moves in business, and what they teach, as they publish.